Warning Letter — Terramed
The FDA issued a Warning Letter to Terramed following an evaluation by the Center for Drug Evaluation and Research (CDER). The source indicates the letter was issued on October 1, 2026, and published on October 6, 2026.
This affects Terramed, as well as personnel involved in regulatory affairs, quality assurance, and manufacturing oversight for the firm's drug products.
A Warning Letter from CDER signifies that the FDA has identified significant violations of regulatory requirements, which often involve deviations from current good manufacturing practice (cGMP). This issuance may lead to administrative actions, such as the withholding of drug approvals or the restriction of product distribution, until the underlying compliance issues are remediated to the agency's satisfaction. The source provides limited detail on the specific nature of the violations.
Review internal quality management systems to ensure alignment with current good manufacturing practice (cGMP) standards and prepare for potential follow-up inspections or requests for corrective action plans. Verify that all manufacturing site registrations and product listings are current and accurate.
FDA Warning Letter issued to: Terramed. 10/01/2026 — Center for Drug Evaluation and Research (CDER). Source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/terramed-735070-10012026
Open in openFDA / FDA.gov